Brought to you by:
Government Grand Rounds: Educating through advocacy
Since the initial launch of the Cancer Moonshot in 2016, the cancer community has made tangible progress towards ambitious goals, including accelerating scientific discovery in cancer, fostering greater collaboration and improving data-sharing. Just last year, U.S. President Joe Biden announced…
End-stage CLTI: Deep-vein arterialization procedure demonstrates amputation-free survival rate of 66% at six months
Six-month results from the PROMISE II trial of the LimFlow deep-vein arterialization system showed an overall amputation-free survival of 66%—“well above” the primary endpoint target of 54%, chief investigator Daniel Clair, MD, told the 2022 Vascular Interventional Advances (VIVA) meeting…
BEST-CLI attracts $3.3m funding injection to continue data analysis
The Novo Nordisk Foundation has made a $3.3 million contribution toward the BEST-CLI (Best endovascular vs. best surgical therapy in patients with critical limb ischemia) clinical trial, the Denmark-based entity has announced. The grant is set to be used by investigators…
CLTI: Translating guidelines into practice
Clinical practice guidelines (CPG) are integral to helping achieve optimal patient care. The Society for Vascular Surgery (SVS) clinical guidelines are evidence-based and the recommendations assist physicians in clinical decision-making in their daily practices. The challenge for practicing physicians “is…
Innovation: ISET audience hears what’s on the horizon for CLTI patients
“I am going to give you reasons to be excited about your critical limb practice,” Peter Schneider, MD, professor of vascular and endovascular surgery at the University of California San Francisco, told delegates attending the International Symposium on Endovascular Therapy…
Journal of Critical Limb Ischemia set to launch in spring
The CLI Global Society is launching the first peer-reviewed academic journal focusing on interventional techniques pertaining to critical limb ischemia (CLI). The new title, Journal of Critical Limb Ischemia, will appear in the spring. According to the CLI Global Society, the…
FDA panel recommends against premarket approval of Lutonix 014 DCB for BTK use
A Food and Drug Administration (FDA) advisory panel has recommended against premarket approval of BD’s Lutonix 014 drug-coated balloon (DCB) for use in below-the-knee (BTK) arteries. In a meeting on Feb. 17, the majority of the FDA Cardiovascular Devices Panel concluded that…
First US commercial use of Tack Endovascular System in BTK arteries announced
Intact Vascular has announced the first commercial use of its Tack Endovascular System (4F) in multiple sites across the United States. Notably the first Food and Drug Administration (FDA)-approved vascular implant for below-the-knee (BTK), post-angioplasty dissection repair, Tack implants are designed…
Aspirin plus rivaroxaban significantly lowers adverse events in PAD revascularization
Treatment with aspirin plus rivaroxaban following lower-extremity revascularization in patients with peripheral arterial disease (PAD) leads to a 15% reduction in the risk of major adverse limb and cardiovascular events when compared with aspirin alone. The VOYAGER PAD study was…